Association of Fcγ receptor polymorphism and anti-infliximab antibody (AIA) with infliximab-related outcome
| Infusion reaction during 52 weeks | Adherence to infliximab during 52 weeks | ||||||
|---|---|---|---|---|---|---|---|
| Subject | Total (n=96) | Yes (n=17) | No (n=79) | p Value | Continued (n=46) | Discontinued (n=50) | p Value |
| FCGR3A 176F/V | |||||||
| F/F | 44 (46) | 7 (41) | 37 (47) | 0.58 | 22 (48) | 22 (44) | 0.53 |
| F/V | 46 (48) | 8 (47) | 38 (48) | 20 (44) | 26 (52) | ||
| V/V | 6 (6) | 2 (12) | 4 (5) | 4 (9) | 2 (4) | ||
| FCGR3B NA1/NA2 | |||||||
| NA1/NA1 | 42 (44) | 13 (77) | 29 (37) | 0.01* | 16 (35) | 26 (52) | 0.23 |
| NA1/NA2 | 32 (33) | 3 (18) | 29 (37) | 18 (39) | 14 (28) | ||
| NA2/NA2 | 22 (23) | 1 (6) | 21 (27) | 12 (26) | 10 (20) | ||
| AIA | |||||||
| (+) | 18 (19) | 11 (65) | 7 (9) | <0.01* | 7 (15) | 11 (22) | 0.40 |
| (−) | 78 (81) | 6 (35) | 72 (91) | 39 (85) | 39 (78) | ||
Values are numbers (%) unless otherwise indicated.